Intrexon Corp  

(Public, NYSE:XON)   Watch this stock  
Find more results for XON
+0.26 (1.54%)
Mar 16 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 16.66 - 17.32
52 week 10.26 - 26.99
Open 16.83
Vol / Avg. 1.32M/1.60M
Mkt cap 2.17B
P/E     -
Div/yield     -
EPS -0.25
Shares 129.07M
Beta 1.32
Inst. own 78%
May 8, 2018
Q1 2018 Intrexon Corp Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Mar 1, 2018
Q4 2017 Intrexon Corp Earnings Call - Webcast
Mar 1, 2018
Q4 2017 Intrexon Corp Earnings Release
Jan 10, 2018
Intrexon Corp at JPMorgan Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '17) 2017
Net profit margin 69.43% -17.06%
Operating margin -34.39% -59.70%
EBITD margin - -38.73%
Return on average assets 24.58% -4.39%
Return on average equity 45.22% -5.41%
Employees 906 -
CDP Score - -


1750 Kraft Dr Ste 1400
BLACKSBURG, VA 24060-6147
United States - Map
+1-301-5569809 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company's domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company's synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale. The Company's technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing (LEAP), and ActoBiotics platform.

Officers and directors

Randal J. Kirk Chairman of the Board, Chief Executive Officer
Age: 63
Bio & Compensation  - Reuters
Thomas D. Reed Ph.D. Founder, Chief Science Officer
Age: 51
Bio & Compensation  - Reuters
Rick L. Sterling CPA Chief Financial Officer
Age: 53
Bio & Compensation  - Reuters
Thomas Bostick Ph.D. Chief Operating Officer
Bio & Compensation  - Reuters
Joel Liffmann Senior Vice President - Finance
Age: 56
Bio & Compensation  - Reuters
Jack Anthony Bobo Senior Vice President, Chief Communications Officer
Age: 51
Bio & Compensation  - Reuters
Ena Chan Cratsenburg Senior Vice President - Consumer Sector
Age: 48
Bio & Compensation  - Reuters
Jeffrey T. Perez Senior Vice President — Intellectual Property Affairs
Age: 45
Bio & Compensation  - Reuters
Christopher Basta Vice President - Investor Relations
Bio & Compensation  - Reuters
Donald P. Lehr Chief Legal Officer
Age: 42
Bio & Compensation  - Reuters